AC
ACIU.US AC Immune Ltd
- Market cap
- USD 209M
- P/E
- -
- P/B
- 6.53x
- ROE
- -107.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ACIU.US undervalued?
Graham numberThe Graham number of AC Immune Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AC Immune Ltd fundamental analysis
No fundamental analysis for AC Immune Ltd yet.
AC Immune Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab…
Full company profileAC Immune Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AC Immune Ltd annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 23.2M | 20.3M | 7.19M | 110M | 15.4M | 944K | 3.94M | 14.8M | 27.3M | 3.57M | 26.0M |
| Gross Profit | -2.56M | -12.4M | -37.1M | 60.0M | -44.1M | -62.3M | 3.94M | -39.8M | -35.3M | 3.57M | 26.0M |
| Operating Income | -10.5M | -22.5M | -49.6M | 44.5M | -61.3M | -79.0M | -70.8M | -53.6M | -52.4M | -68.9M | -31.2M |
| EBITDA | -6.81M | -22.5M | -49.7M | 46.2M | -59.3M | -70.0M | -68.0M | -51.8M | -48.6M | -67.8M | -28.7M |
| Net Income | -7.10M | -26.4M | -51.0M | 45.4M | -61.9M | -73.0M | -70.8M | -54.2M | -50.9M | -70.4M | -28.9M |
| EPS | -0.14 | -0.46 | -0.82 | 0.64 | -0.86 | -0.97 | -0.85 | -0.64 | -0.51 | -0.70 | -0.29 |
| Balance Sheet | |||||||||||
| Total Assets | 156M | 132M | 197M | 299M | 239M | 261M | 186M | 183M | 231M | 154M | 139M |
| Total Liabilities | 13.7M | 15.2M | 18.9M | 26.8M | 23.3M | 29.5M | 16.9M | 22.2M | 119M | 109M | 112M |
| Shareholders' Equity | 142M | 117M | 178M | 272M | 215M | 232M | 169M | 161M | 112M | 44.9M | 26.9M |
| Cash & Short-term Investments | 152M | 124M | 186M | 289M | 226M | 198M | 123M | 103M | 165M | 91.4M | 18.7M |
| Total Debt | 0.00 | 498K | 552K | 2.91M | 2.22M | 2.91M | 2.80M | 3.50M | 5.43M | 4.55M | 3.90M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.65M | -22.1M | -44.1M | 55.2M | -59.5M | -65.7M | -73.6M | -60.4M | 65.8M | -66.1M | - |
| Capital Expenditure | 899K | 1.80M | 1.86M | 1.89M | 1.71M | 2.64M | 1.24M | 801K | 576K | 860K | 0.00 |
| Free Cash Flow | -6.55M | -23.9M | -45.9M | 53.3M | -61.2M | -68.3M | -74.8M | -61.2M | 65.3M | -67.0M | - |
| Ratios | |||||||||||
| ROE | -5.0% | -22.6% | -28.7% | 16.7% | -28.7% | -31.5% | -41.9% | -33.8% | -45.4% | -156.8% | -107.3% |
| ROA | -4.5% | -20.0% | -25.9% | 15.2% | -25.9% | -27.9% | -38.1% | -29.7% | -22.0% | -45.6% | -20.8% |
| Net Profit Margin | -30.6% | -130.4% | -708.2% | 41.1% | -401.3% | -7,732.6% | -1,798.0% | -366.4% | -186.4% | -1,971.6% | -111.3% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.02x | 0.02x | 0.05x | 0.10x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AC Immune Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | CHF 7.00K | 0.00 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns AC Immune Ltd
- Insiders 38.09%
- Institutions 24.34%
- Public & others 37.57%
- Shares outstanding 99.4M
- Free float 26.5M
Top funds holding ACIU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Biotechnology ETF | 478K | 0.48% | -0.19% | Oct 2026 |
| Monega ARIAD Innovation R | 92.4K | 0.09% | 0.00% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 83.9K | 0.08% | +0.21% | Oct 2026 |
| Dimensional US Small Cap ETF | 80.7K | 0.08% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 69.9K | 0.07% | 0.00% | Aug 2026 |
| DFA U.S. Small Cap I | 45.4K | 0.05% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 44.1K | 0.04% | 0.00% | Sep 2026 |
| Top Class Healthcare FI | 40.0K | 0.04% | 0.00% | Sep 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 16.2K | 0.02% | -1.01% | Jun 2026 |
| DFA U.S. Vector Equity I | 15.8K | 0.02% | 0.00% | Sep 2026 |
| Dimensional Global Small Coms USD Acc | 12.2K | 0.01% | 0.00% | Sep 2026 |
| Dimensional World Equity GBP Acc | 11.9K | 0.01% | -0.22% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 9.94K | 0.01% | -0.40% | Sep 2026 |
| Dimensional International Core Eq Acc | 9.82K | 0.01% | 0.00% | Sep 2026 |
| JNL/DFA US Small Cap A | 7.97K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 7.86K | 0.01% | 0.00% | Oct 2026 |
| Dimensional World Allc 60/40 GBP Acc | 7.85K | 0.01% | 0.00% | Sep 2026 |
| Invesco Nasdaq Biotechnology ETF | 7.78K | 0.01% | 0.00% | Oct 2026 |
| JNL/DFA US Core Equity A | 7.70K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Sm Company EUR Acc | 6.98K | 0.01% | -0.30% | Sep 2026 |
Top institutions holding ACIU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bvf Inc | 19.8M | 19.94% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 1.00M | 1.01% | -0.02% | Jun 2026 |
| Renaissance Technologies Corp | 840K | 0.85% | +34.56% | Jun 2026 |
| Millennium Management LLC | 774K | 0.78% | -2.40% | Jun 2026 |
| BlackRock Inc | 519K | 0.52% | -0.95% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 349K | 0.35% | +2.72% | Sep 2026 |
| Arrowstreet Capital Limited Partnership | 233K | 0.23% | -42.57% | Jun 2026 |
| Citadel Advisors Llc | 208K | 0.21% | -22.31% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 132K | 0.13% | +47.69% | Jun 2026 |
| Two Sigma Investments LLC | 103K | 0.10% | +163.04% | Jun 2026 |
| Qube Research & Technologies | 92.4K | 0.09% | 0.00% | Jun 2026 |
| UBS Group AG | 85.6K | 0.09% | -15.76% | Jun 2026 |
| Geode Capital Management, LLC | 61.9K | 0.06% | -2.75% | Jun 2026 |
| Susquehanna International Group, LLP | 53.4K | 0.05% | -40.21% | Jun 2026 |
| Jump Financial LLC | 24.1K | 0.02% | +116.31% | Jun 2026 |
| Jane Street Group LLC | 19.5K | 0.02% | -66.25% | Jun 2026 |
| Verdad Advisers, LP | 16.3K | 0.02% | 0.00% | Jun 2026 |
| China Universal Asset Mgmt Co.Ltd | 16.2K | 0.02% | -9.27% | Jun 2026 |
| The Goldman Sachs Group Inc | 14.5K | 0.01% | -32.98% | Jun 2026 |
| Quadrature Capital Limited | 13.0K | 0.01% | 0.00% | Jun 2026 |
AC Immune Ltd company profile
- Company name
- AC Immune Ltd
- Ticker
- ACIU.US
- ISIN
- CH0329023102
- Exchange
- USA Stocks
- Listed since
- Sep 23, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 90
- Fiscal year end
- December
- Address
- Building B, Lausanne, Switzerland, 1015
- Phone
- 41 21 345 91 21
- Website
- acimmune.com
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
AC Immune Ltd management
10- Mr. Christopher RobertsCFO & VP of Finance · born 1989
- Mr. Piergiorgio DonatiChief Operating Officer · born 1971
- Dr. Martin Zugel M.D., Ph.D.Interim CEO & Chairman of the Board · born 1963
- Dr. Gary Anthony Waanders Ph.D.Senior VP of Investor Relations & Corporate Communications · born 1964
- Dr. Matthias Maurer Ph.D.Senior VP & General Counsel · born 1982
- Dr. Oliver Sol M.D.VP & Head of Clinical Development · born 1967
- Dr. Julien Rongere Ph.D.Senior Vice President of Regulatory Affairs & Quality Assurance · born 1978
- Mr. Mark DantonExecutive Vice President of Information Systems & Artificial Intelligence · born 1964
- Dr. Günther Staffler Ph.D.Executive Vice President of Development · born 1969
- Dr. Francesca CapotostiSenior Vice President of Research